Leqembi gets accelerated approval from FDA to treat Alzheimer's

A newly approved drug for Alzheimer's disease is providing a sense of hope for some people fighting the disease. The Food and Drug Administration on Friday granted accelerated approval to lecanemab, which will be sold under the name Leqembi, after clinical trials showed the drug slows cognitive decline in patients with early Alzheimer's disease. The treatment is a monoclonal antibody infusion given to patients biweekly. Some questions and concerns remain about the drug's safety, and how most people will afford the treatment, but even still, FDA approval is enough reason for Dennis Myers to be optimistic. Time is of the essence for Myers, who has early Alzheimer's disease, to have more time with family and more time with the memories he holds dear.